Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive Geno- and Phenotyping in 5-FU or Capecitabine-treated Patients
NCT04269369Phase 4Unknown
- Sponsor
- Jessa Hospital
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 4 trial of fluorouracil, capecitabine in colon cancer, gastric cancer (GC), anal cancer, pancreatic cancer (PC), esophageal cancer, sponsored by Jessa Hospital. Status: unknown.
02
Drugs
fluorouracilcapecitabine
03
Conditions
colon cancergastric cancer (GC)anal cancerpancreatic cancer (PC)esophageal cancer
Beyond the preview
Go deeper on NCT04269369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269369.